NeuraLight

A new paper validates the importance of #eyemovements in #Parkinson's disease, serving as a tool for preliminary screening https://t.ly/Sm9L9

Anti-saccade #eyemovements are effective in the assessment of #cognitive impairment, serving as an initial #screening tool for detecting Mild Cogntitive Impairement #MCI https://t.ly/WI_CL

A new review of the current strategies for treating #Parkinson's disease, and the continuous search for reliable #biomarkers to monitor disease progression #eyemovements https://t.ly/iT9-p

A new paper in Frontiers: Abnormal #eyemovements have a considerable predictive value for the diagnosis and progression of #Alzheimer's disease https://t.ly/eTos3

Findings of a new study from University of Cambridge on the effect of #atomoxetine, a noradrenaline reuptake inhibitor, on the #eyemovements patients with #Parkinson's disease, suggest that the #oculomotor system can support the assessment of #cognitive effects without limb-motor confounds on task performance. https://t.ly/MjDCc

Results of a new review paper from University of Oxford highlight some consistent differences in #eyemovements between people with #Parkinson's disease and healthy aging in naturalistic scenarios https://t.ly/4ED9i

A new published paper from Universidad Nacional Autónoma de México on patients with early #Huntington's disease #HD who revealed abnormalities of #eyemovements, suggestive the involvement of brain stem deficits https://t.ly/QbsXn

In these days, as the 2024 #NobelPrize announcements are made by The Royal Swedish Academy of Sciences and the Karolinska Institutet, this is a good opportunity to express our gratitude to the distinguished members of NeuraLight advisory board, #NobelPrize laureates Prof. Thomas C. Südhof, MD, PhD, and Prof. Alvin Roth, PhD for their exceptional contribution to the development of #science, #medicine and #healthcare. Thank you! https://t.ly/e5464

Over the last decades, a large evidence-based knowledge was gathered on the role of #eyemovements as a window to the #brain in #CNS diseases. Check our new NeuraLight website to find out more on the science behind out technology https://t.ly/-PRk8

#Eyemovements have been known for decades as a relevant assessment tool for #Alzheimer's disease. This new study examined changes in pupillary responses as potential #biomarkers in patients with mild cognitive impairment #MCI https://t.ly/kPsbw